Phase III Data, FDA Interactions Bode Well For Portola’s Factor Xa Antidote
This article was originally published in The Pink Sheet Daily
Executive Summary
Breakthrough drug andexanet alfa meets all endpoints for reversing effects of Bristol/Pfizer’s Eliquis in Phase III, bringing the company a step closer to a filing for an accelerated approval by year’s end.
You may also be interested in...
The Antidote To Competition: Portola’s Rivals Fund Study On Class-Wide Anticoagulant Antidote
Although one day it may compete with Bristol-Myers Squibb and Pfizer in the market for anticoagulant Factor Xa inhibitors, Portola has partnered with the two pharmas to fund a study on its class-wide antidote compound that prevents serious bleeding events.
Rare Disease Roundtable: Dealing With Pricing Pressure
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.
Rare Disease Roundtable: How Rare Is Too Rare?
Part 1: Execs from rare disease-focused companies weighed in on investor sentiment during a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference.